Skip to content

A compararision to know the effect of Vidalak and Aschyotan kriyakalp (a type of procedure) in the management of Kaphaj Abhishyanda with special reference to Allergic Conjunctivitis.

A comparative clinical study to evaluate the efficacy of Vidalak and Aschyotan kriyakalp in the management of Kaphaj Abhishyanda with special reference to Allergic Conjunctivitis. - ACEVAKA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032953
Enrollment
80
Registered
2021-04-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H108- Other conjunctivitis

Interventions

Intervention1: Aschyotan(eye drop) Vidalak: Group 1 :- 20 patients will be administered Vidalak kriyakalp for local application for one month. Group 2 :- 20 patients will be administered Aschyotan (ey

Sponsors

Banaras Hindu University varanasi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Presenting with clinical features ofallergic conjunctivitis Age between 5-60 years. Patient willing to participate in the study by giving the informed consent. Pt not having any systematic disorders like DM, HTN, CAD as well as other eye aliments

Exclusion criteria

Exclusion criteria: Patients with other severe complication. Patient have other type of conjunctivitis. Conjunctivitis in childrens Other systemic disorder. Patient having history of ocular surgery within 3 month of study will not be taken. Patient who start developing complications will be excluded from the study. Patient not willing for the treatment.

Design outcomes

Primary

MeasureTime frame
sign and symptoms of allergic conjunctivitis Timepoint: 2 month

Secondary

MeasureTime frame
Slit lamp examination CBC ESR & AEC Timepoint: 2 month

Countries

India

Contacts

Public ContactDr B Mukhopadhyay

Banaras Hindu University

drbijoy123@rediffmail.com7905827622

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026